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Abstract
Stereotactic Radiosurgery (SRS) is considered standard of care for patients with
1–3 brain metastases (BM). Recent observational studies have shown equivalent
OS in patients with 5+ BM compared to those with 2–4, suggesting SRS alone
may be appropriate in these patients. We aim to review outcomes of patients
treated with SRS with 2–4 versus 5+ BM. This analysis included consecutive
patients from 1994 to 2015 treated with SRS. Of 1017 patients, we excluded
patients with a single BM and patients without adequate survival data, resulting
in 391 patients. All risk factors were entered into univariate analysis using Cox
proportional hazards model, and significant factors were entered into multivariate analysis (MVA). We additionally analyzed outcomes after excluding patients
with prior surgery or whole-brain radiotherapy (WBRT). Median follow-up was
7.1 months. Median KPS was 90, mean age was 59, and most common histologies were melanoma and lung. Median tumor volume was 3.41 cc. Patients
with 2–4 BM had a median OS of 8.1 months compared to 6.2 months for
those with 5+ BM (P = 0.0136). On MVA, tumor volume, KPS, and histology
remained significant for OS, whereas lesion number did not. Similar results
were found when excluding patients with prior surgery or WBRT. Rather than
lesion number, the strongest prognostic factors for patients undergoing SRS
were tumor volume >10 cc, KPS, and histology. BM number may therefore
not be the most important criterion for candidacy for SRS. Patients with 5 or
more BM should be considered for SRS.

Introduction
Brain metastases (BM) develop in up to 20–40% of patients
diagnosed with cancer, and the incidence is increasing as
cancer patients are living longer with improving systemic
therapy [1, 2]. Radiation therapy (RT) is an integral component of the treatment of BM to improve local control,
and in certain instances, overall survival (OS). Whole-brain
radiation therapy (WBRT) has traditionally been the standard
for patients with multiple BM. However, there has been a
trend toward increased use of stereotactic radiosurgery (SRS)
for management of patients with single or <4 BM [3, 4].

The efficacy and toxicity of WBRT in comparison with
and in addition to SRS have been evaluated in a randomized fashion and in a meta-analysis [5]. Recent trials
have shown the addition of WBRT to SRS does not
improve survival outcomes, and WBRT causes significant
declines in neurocognition and overall quality of life (QOL)
for patients with 1–3 BM [6, 7]. For example, Alliance
trial N0574 randomized patients with 1–3 BM to SRS
versus SRS with WBRT and found no statistically significant difference in median OS, 10.4 months versus
7.4 months, respectively (P = 0.92). While WBRT after
SRS improved local and regional control, it had no impact
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on OS and was associated with decreased cognitive function and decreased quality of life 3 months after treatment
[7].
Furthermore, SRS can be performed in a single fraction
which is more convenient for patients. Often, patients
will require an interruption in systemic therapy while
undergoing WBRT due to concern regarding increased
toxicity with concurrent treatment. Thus, patients treated
with SRS may end up ultimately receiving more systemic
therapy in comparison with those undergoing WBRT [8].
This is an especially important consideration in the age
of newer targeted agents that can significantly impact
survival and disease burden.
Stereotactic radiosurgery alone or in combination with
other modalities is therefore generally accepted as the
standard of care for patients with 1–3 BM. However,
debate and uncertainty regarding the optimal management
of patients with 4–5 or more BM remains. Yamamoto
et al. have suggested equivalent outcomes for patients
with four or more BM treated with SRS in comparison
with patients with fewer BM [9, 10]. There are no published randomized trials for SRS versus WBRT for patients
with five or more BM.
In the absence of level 1 evidence addressing the optimal
management of patients presenting with multiple BM, the
aim of this study was to compare OS and identify prognostic factors in patients with 2–4 versus 5 or more BM.
This analysis further elucidates considerations for the use
of SRS in patients with more than 4 BM by reviewing
patients treated at a single institution over the last two
decades.

Methods
Study population
Institutional review board approval was obtained and
retrospective review was performed of all consecutive
patients with BM treated with SRS at our institution from
1994 to 2015. We included patients with two or more
treated BM, and excluded patients who were missing critical baseline, treatment, or survival information. We additionally analyzed outcomes after excluding patients who
were treated with prior neurosurgical resection or WBRT.
We obtained patient and treatment information from
electronic medical records and survival data from the
institutional cancer registry.

Radiation delivery
All patients were treated with single-fraction Gamma Knife
radiosurgery. Gamma Knife (Elekta Instruments Inc.)
Model U was used from 1994 to 2000, Model C was
758
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used from 2000 to 2008, and Perfexion was used from
2008 to 2015. All patients were immobilized with a stereotactic head frame. The frame application was performed
by a neurosurgeon utilizing four pins affixed to the cranium after the patient was provided conscious sedation
by a member of the anesthesia team. Contrast-enhanced
thin slice magnetic resonance imaging (MRI) of the brain
was then performed for target delineation and treatment
planning.
Dose prescription was at the discretion of the treating
team and in general accordance with RTOG 90-05. For
tumor diameter <2 cm, prescription was 20–24 Gy typically to 50% isodoline line. For tumors >2 cm and <3 cm
diameter, dose was generally 18 Gy to 50% isodose line.
For tumors >3 cm, we typically prescribe 15 Gy to 50%
isodoseline. This prescription guideline is not modified
for various primary cancers including nonsmall cell lung
cancer, breast cancer, melanoma, renal cell cancer, and
colorectal cancer. Tumor equivalent volumes are converted
using the formula for volume of a sphere, (4/3) * π *
r3. A 2-cm-diameter cutoff corresponds to 4.19 cc volumetric cutoff. A 3-cm-diameter cutoff corresponds to a
14.1 cc volumetric cutoff. The decision to leave BM
untreated at the time of SRS was per the radiation oncologist and neurosurgeon at the time of treatment, with
generally small and asymptomatic BM as lesions less likely
to be treated [11].

Statistical analysis
The primary endpoint was overall survival (OS) in months.
Time was calculated from the date of initial SRS treatment to the date of death. Censoring occurred at the
date the patient was last known to be alive. All risk factors were defined at the time of initial SRS. Analyzed
risk factors for survival included age, sex, tumor histology,
performance status, graded prognostic assessment (GPA)
score, recursive partitioning analysis (RPA) class, synchronous or metachronous diagnosis of BM, increase in number
of BM from initial consultation to treatment, untreated
BM, infratentorial BM, number of BM treated, total tumor
volume (continuous and categorical <5 cc, 5–10 cc, >10 cc),
and SRS dose.
Performance status was graded with the Karnofsky
Performance Score (KPS) on a scale of 0 to 100. GPA
was scored from 0 to 4 based on age, KPS, number of
BM, and the presence of extracranial metastases [12]. RPA
was scored from 1 to 3 based on age, KPS, control of
primary disease, and the presence of extracranial metastases
[13]. Synchronous diagnosis of BM was defined as discovery
of BM within 3 months of the diagnosis of the primary
cancer. Progression of BM was defined as an increase in
number of identified BM between the initial diagnostic
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MRI and the MRI on the day of SRS treatment. Patients
were defined as having untreated BM if not all identified
BM were targeted with SRS. The total tumor volume is
the total volume of BM treated with SRS as measured on
MRI using Leksell GammaPlan (Elekta Inc. Stockholm,
Sweden) software.
Baseline variables were compared using the Wilcoxon
rank sum test, Pearson’s chi-squared test, and Fisher’s exact
test. OS was analyzed using the Kaplan–Meier method with
significance testing with the log rank test. We performed
two analyses; Analysis 1 included all patients. Analysis 2
excluded patients with prior neurosurgical resection or
WBRT. All risk factors were entered into univariate analysis
using the Cox proportional hazards model. Significant risk
factors were further entered into multivariate analysis, except
GPA and RPA scores given these measures represent a
composite of other investigated factors. JMP Pro 13 (SAS
Institute Cary, NC) was used to perform the analyses. All
P-values were two-sided with a significance level of 0.05.

Results
Of 1017 eligible patients treated with SRS for BM between
1994 and 2015, patients with one lesion (543 patients)
and patients missing survival or baseline data (83 patients)
were excluded, thereby resulting in 391 patients who were
included in the analysis.
All patients were analyzed regardless of prior WBRT
or neurosurgical resection. Baseline characteristics are
presented in Table 1. Patients with 5 or more BM had
a higher rate of untreated BM and progressive BM from
baseline as well as a lower GPA compared to patients
with 2–4 BM. Of note, there were no significant differences in total tumor volume between the cohorts.
With a median follow-up of 7.1 months, patients with
2–4 BM (n = 314) had a median OS of 8.1 months and
patients with 5 or more BM (n = 77) had a median OS
of 6.2 months (P = 0.0136) (Fig. 1A). Prognostic factors
with a significant effect on OS on univariate analysis included

Table 1. Baseline patient and treatment characteristics.
2–4 (n = 314)
Age, median (range)
Sex
Male
Female
Histology
Breast adenocarcinoma
Lung NSCLC
Melanoma
Renal cell carcinoma
Other
KPS median (range)
GPA, median (range)
RPA
Class 1
Class 2
Class 3
Brain mets diagnosed
within 3 months of
primary
Increase in # of brain mets
from baseline to
treatment
Untreated brain mets
Infratentorial brain mets
SRS dose, Gy, median
(range)
Total tumor volume, cc,
median (range)
Total tumor volume, cc
<5
5–10
>10

60 (13–100)

5+ (n = 77)
55 (29–100)

All (n = 391)
59 (13–100)

P-value
0.11

172 (55%)
142 (45%)

45 (58%)
32 (42%)

217 (56%)
174 (44%)

0.56

46 (15%)
59 (19%)
140 (45%)
25 (8%)
39 (13%)
90 (50–100)
2 (0–3.5)

9 (12%)
10 (13%)
45 (60%)
4 (5%)
7 (9%)
90 (40–100)
1.5 (0.5–3)

55 (14%)
69 (18%)
185 (48%)
29 (8%)
46 (12%)
90 (40–100)
1.5 (0–3.5)

0.26

46 (15%)
247 (80%)
15 (5%)
42 (16%)

6 (8%)
66 (89%)
2 (3%)
11 (17%)

52 (14%)
313 (82%)
17 (4%)
53 (16%)

0.88

101 (32%)

47 (61%)

148 (38%)

<0.0001

48 (15%)
113 (36%)
18 (12–22)

19 (25%)
33 (43%)
18 (14–20)

67 (17%)
146 (37%)
18 (12–22)

0.05
0.06
0.07

3.41 (0.071–81.60)

0.43

239 (61%)
72 (19%)
78 (20%)

0.67

3.36 (0.07–36.02)

195 (62%)
58 (19%)
60 (19%)

3.53 (0.29–81.60)

44 (58%)
14 (18%)
18 (24%)

0.89
<0.0001
0.20

NSCLC, Nonsmall Cell Lung Cancer; KPS, Karnofsky Performance Status; GPA, Grade Prognostic Assessment; RPA, Recursive Partitioning Analysis;
mets, metastases; SRS, Stereotactic Radiosurgery.
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lesion number, total tumor volume, histology, untreated
BM, KPS, GPA, and RPA. Tumor volume >10 cc had a
hazard ratio (HR) of 1.451 for worse OS when compared
to tumor volume <5 cc (P = 0.010) (Fig. 1B). Tumor
volume was also significantly associated with worse OS
when analyzed as a continuous variable (P = 0.0314). Breast
histology had the best OS with melanoma, lung, and other
categories faring significantly worse (Fig. 1C). Lung primaries
(nonsmall cell lung cancer) and other histologies (including
small cell lung cancer, colorectal, prostate, ovarian) had
the worst outcomes with HRs of 1.557 and 2.463, respectively, in comparison with patients with breast cancer. On
multivariate analysis, only total tumor volume, KPS, and
histology remained significant (Table 2).
To further analyze the relationship of tumor volume
and lesion number, a standard least squared regression
model was used. There was a statistically significant but
weak correlation between the two (R2 = 0.045, P < 0.0001).
The number of BM only accounted for 4.5% of the variance in total tumor volume. Figure 2 displays this relationship of volume by lesion number in a box plot.

D. M. Routman et al.

After excluding 121 patients with prior surgery (n = 77)
and/or WBRT (n = 58), the difference in median OS
was not significantly different on univariate (P = 0.0603)
or multivariate (P = 0.2772) analysis when comparing
2–4 BM (n = 219) to 5 or more BM (n = 52) (Tables
S1 and S2). Histology, KPS, GPA, RPA, and total tumor
volume were significantly associated with OS on univariate
analysis. On multivariate analysis, total tumor volume
(both as a categorical and as a continuous variable), KPS,
and histology remained significant, consistent with the
primary analysis of all patients.
We further analyzed the data to attempt to develop a
metric for identifying patients with the worst prognosis
where consideration of best supportive care may be warranted. Given the median OS of breast cancer histology
(14.72 months) versus all nonbreast histology (median OS
7.18 months; P = 0.006), we examined all patients with
nonbreast cancer. Seventy-
eight patients with nonbreast
histology had OS <3 months. Of these, 21 had total tumor
volume >10 cc. Nine had total tumor volume >10 cc and
KPS <80. We found those with total tumor volume >10 cc

Figure 1. Kaplan–Meier survival curves of (A) number of brain metastases by category (B) tumor volume by category (C) histology (D) risk category.
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Table 2. Univariate and multivariate Cox proportional hazards model of overall survival.
Variables

Number of BM treated
2–4
5+
Age
≤60 years
>60 years
Sex
Male
Female
Histology
Breast adenocarcinoma
Lung NSCLC
Melanoma
Renal cell carcinoma
Other
KPS
90–100
70–80
≤60
GPA
0–1
1.5–2.5
3–4
RPA
Class 1
Class 2
Class 3
Synchronous BM
Increase in number of BM
from baseline to
treatment
Untreated BM
Infratentorial BM
SRS dose
SRS dose
<18 Gy
≥18 Gy
Total tumor volume
<5 ccs
5–10 ccs
>10 ccs

Univariate

Multivariate

HR (95% CI)

P-value

HR (95% CI)

P-value

Ref.
1.396 (1.062–1.810)

Ref.
0.0176

Ref.
1.220 (0.903–1.624)

Ref.
0.1921

Ref.
1.228 (0.991–1.521)

Ref.
0.0604

Ref.
1.201 (0.957–1.505)

Ref.
0.1143

Ref.
0.877

Ref.
0.2272

–
–

–
–

Ref.
1.557 (1.059–2.291)
1.473 (1.059–2.049)
1.180 (0.725–1.922)
2.463 (1.596–3.800)

Ref.
0.0236
0.0173
0.5085
<0.0001

Ref.
1.664 (1.110–2.497)
1.422 (0.997–2.009)
1.053 (0.641–1.730)
1.947 (1.231–3.079)

Ref.
0.0134
0.0397
0.8395
0.0049

Ref.
1.533 (1.219–1.922)
2.690 (1.542–4.369)

Ref.
0.0003
0.0010

Ref.
1.417 (1.111–1.802)
2.340 (1.301–3.912)

Ref.
0.0052
0.0059

Ref.
0.686 (0.537–0.883)
0.514 (0.330–0.777)

Ref.
0.0037
0.0013

–
–
–

–
–
–

Ref.
1.129 (0.827–1.579)
2.394 (1.305–4.177)
1.139 (0.815–1.556)
0.908 (0.725–1.131)

Ref.
0.4546
0.0059
0.4351
0.3911

–
–
–
–
–

–
–
–
–
–

1.436 (1.078–1.882)
1.140 (0.915–1.415)
0.961 (0.915–1.013)

0.0142
0.2418
0.1394

1.321 (0.977–1.757)
–
–

0.0701
–
–

Ref.
1.141 (0.870–1.477)

Ref.
0.3323

–
–

–
–

Ref.
1.223 (0.916–1.610)
1.451 (1.094–1.900)

Ref.
0.1682
0.0103

Ref.
1.326 (0.979–1.768)
1.641 (1.217–2.186)

Ref.
0.0678
0.0014

NSCLC, Nonsmall Cell Lung Cancer; KPS, Karnofsky Performance Status; GPA, Grade Prognostic Assessment; RPA, Recursive Partitioning Analysis;
mets, metastases; SRS, Stereotactic Radiosurgery.

and KPS <80 had a median OS of 1.63 months compared
to 7.87 months for all patients that did not meet all these
criteria (P = 0.02). The KM survival curves based on these
criteria are presented in Figure 1D.

Discussion
Many radiation oncologists use lesion number as an important consideration when deciding on an optimal treatment
strategy of SRS versus WBRT for BM. In a survey of

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

practicing radiation oncologists by Sandler et al., number
of lesions was identified as the most important factor in
decision making for selecting WBRT versus SRS—more
important than performance status, size of lesions, extracranial disease status, histology, and patient convenience.
Furthermore, non-
CNS specialists (as defined by patient
volume) were more likely to pick a lower number for the
cutoff of when to no longer treat with SRS (mean 5.1
BM) versus CNS specialists (mean 8.1 BM), with a mean
cutoff closer to four for minimal volume providers. Most
761
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Figure 2. Box plot of tumor volume versus number of brain metastases
with linear regression.

radiation oncologists listed four to six lesions as the cohort
they found most challenging in deciding how to treat [4].
However, prior studies as well as our analysis demonstrate
that although lesion number is an easily quantifiable metric,
it is not necessarily the best factor in determining optimal
candidacy for SRS.
In a prospective observational trial (JLGK0901), patients
with 2–4 BM (n = 531) and 5 or more BM (n = 208)
had equivalent median survivals of 10.8 months (P = 0.78).
There was no difference in the rate of neurologic death
or local recurrence between the two groups [10]. Our
findings are consistent with these results. Although median
OS for all patients significantly favored the 2–4 group on
univariate analysis (8.13 months vs. 6.23 months,
P = 0.0176), on MVA, the difference was no longer statistically significant (P = 0.2714). This result was true for
all patients including those with prior WBRT and/or surgery
as well as when patients were excluded that had prior
WBRT and/or surgery. For patients not receiving prior
WBRT and/or surgery, lesion number was not significant
on univariate (P = 0.0603) or MVA (P = 0.2772).
Yamamoto et al. concluded that radiosurgery alone for
patients with 5 or more BM was noninferior to outcomes
with SRS alone in patients with 2–4 BM. Their group
further evaluated patients with 10 or more BM treated
with SRS in a propensity score case-matched analysis and
found no difference between groups for OS or neurologic
death as well as other measures such as local recurrence,
repeat SRS for new lesions, or complications [9]. Additional
evidence comes from prior retrospective series including
Chang et al. [14], who found no difference in regard to
outcomes after SRS for patients with 1–5, 6–10, 11–15
or even more metastases.
Tumor volume may be more important in terms of
prognostication than lesion number. In the current series,
tumor volume >10 cc was associated with worse OS
762

D. M. Routman et al.

(HR = 1.451). Multiple prior series have found similar
results regarding the association between increasing tumor
volume and worse outcomes. Bhatnagar et al., Likhacheva
et al., and Baschnagel et al., demonstrated that tumor
volume was statistically significantly associated with OS
while number of BM was not [15–17]. Interestingly, this
was true in our series of all patients and excluding patients
with prior WBRT or surgery. Cumulative tumor volume
was likewise significantly associated with worse survival
on univariate analysis in JLGK0901.
Secondary factors including female sex, age <65, KPS
≥80, stable extracranial disease, and the absence of neurologic symptoms were significantly associated with longer
OS in JLGK0901 [10]. In our analysis, histology and KPS
(along with tumor volume) were significantly associated
with OS on MVA. These factors have been studied in
prior series and components utilized in the graded prognostic assessment and in nomograms. While lesion number
is often a factor, tumor volume is rarely included in these
scoring systems [18].
To further investigate the association of the interplay
of number of BM and volume, we looked at the correlation between the two. While increasing number of BM
was significantly correlated with tumor volume, it
accounted for only 5% of the variance. Additionally, we
identified a high-risk cohort, namely histology other than
breast cancer, tumor volume >10 cc, and KPS <80. These
patients had a median OS of <2 months.
This study is limited by its retrospective nature and the
limited scope of patient data, such as lack of information
regarding systemic therapies. These data are subject to
inherent biases including selection bias in that the 5 or
more BM group could represent a select and more favorable
cohort. However, the intent of this analysis was to look
at patients in a clinical setting treated at the discretion of
the consulting radiation oncologist, and the groups were
well balanced with the exception of GPA as described above.
Patients treated over the course of two decades were analyzed, representing a heterogeneous group with many changes
in overall approaches to oncologic care throughout this
time period. However, these results of patients treated at
a single institution over 20 years have practical implications
for current management of the increasingly common patient
presenting with multiple BM, especially in the absence of
a randomized trial. Arbitrarily using a cutoff of 5 or more
metastases is not warranted based on this data and should
not exclude patients from radiosurgery, nor should prior
WBRT or neurosurgical resection.
Current guidelines have clearly delineated recommendations for patients with 4 or fewer metastases but not
for patients with 5 or more lesions in regard to SRS
[19, 20]. A single institution phase III randomized trial
(NCT01592968) currently enrolling patients with 4 or

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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more BM to SRS versus WBRT will ideally provide level
1 evidence regarding optimal management [21].
Ultimately, the decision to treat a patient with more
than 4 BM with SRS depends on a number of clinical
and pathologic factors, including systemic therapeutic
options, prognosis, and the patient’s goals of care. These
factors should be discussed in a multidisciplinary tumor
board setting when possible. Tumor volume in conjunction
with other clinical and pathologic features is likely more
important in terms of prognostication than lesion number
alone, and has recently been shown to improve prognostic
models including disease-specific GPA [22–24].
With the increasingly common use of targeted agents,
delays in systemic therapy secondary to WBRT could
ultimately be detrimental to a patient’s outcome.
Nevertheless, even in the setting of targeted agents, radiotherapy remains an important treatment for patients with
BM and could impact OS [25]. Furthermore, immunotherapy and targeted agents may lead to better tumor
control and reduce distant brain failure, rendering SRS
more impactful [26]. Finally, with close surveillance,
patients that have regional failure after SRS can undergo
effective salvage SRS with low morbidity, providing further
rationale for the upfront use of SRS.

2.

3.

4.

5.

6.

Conclusions

7.

Patients with 5 or more BM treated with SRS have comparable OS to those with 2–4 BM, regardless of prior
WBRT or surgery, and remain good candidates for SRS
based on the results of this study. While number of lesions
may be prognostic, total tumor volume may be a more
important factor in determining OS. Given the side effects
associated with WBRT and equivalent outcomes with SRS
alone, our analysis supports offering SRS alone to select
patients with 5 or more BM with total tumor volume
<10 cc in clinical practice.

8.
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